ARK Genomic Revolution ETF (BATS:ARKG) Sets New 12-Month High – Time to Buy?

ARK Genomic Revolution ETF (BATS:ARKG) hit a new 52-week high on Wednesday . The company traded as high as $46.78 and last traded at $46.14, with a volume of 669417 shares. The stock had previously closed at $43.21.

ARK Genomic Revolution ETF Stock Performance

The company’s 50 day moving average price is $39.94 and its 200 day moving average price is $33.05.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of ARKG. NewEdge Advisors LLC raised its position in shares of ARK Genomic Revolution ETF by 49.4% during the first quarter. NewEdge Advisors LLC now owns 5,384 shares of the company’s stock worth $112,000 after acquiring an additional 1,780 shares during the last quarter. Creative Planning bought a new position in ARK Genomic Revolution ETF in the second quarter valued at about $255,000. Baird Financial Group Inc. increased its position in ARK Genomic Revolution ETF by 81.0% in the second quarter. Baird Financial Group Inc. now owns 71,977 shares of the company’s stock worth $1,753,000 after purchasing an additional 32,221 shares during the period. Strategic Wealth Investment Group LLC acquired a new stake in ARK Genomic Revolution ETF in the second quarter worth about $38,000. Finally, Group One Trading LLC bought a new stake in ARK Genomic Revolution ETF during the 2nd quarter worth about $2,274,000.

ARK Genomic Revolution ETF Company Profile

The ARK Genomic Revolution ETF (ARKG) is an exchange-traded fund that mostly invests in stocks based on a particular theme. The fund is an actively managed fund that targets companies involved in the genomics industry. ARKG was launched on Oct 31, 2014 and is managed by ARK.